Laurion Capital Management LP Tricida, Inc. Transaction History

Laurion Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $180,557 - $292,695	-24,700 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$4.37 - $9.46 $111,872 - $242,176	-25,600 Reduced 50.89%	24,700 $174,000
Q3 2020 Nov 13, 2020	SELL	$8.56 - $26.93 $70,192 - $220,826	-8,200 Reduced 14.02%	50,300 $455,000
Q2 2020 Aug 14, 2020	BUY	$21.21 - $31.55 $1.24 Million - $1.85 Million	58,500 New	58,500 $1.61 Million
Q4 2018 Feb 14, 2019	SELL	$23.57 - $32.33 $2.47 Million - $3.39 Million	-105,000 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$22.5 - $39.35 $450,000 - $787,000	-20,000 Reduced 16.0%	105,000 $3.21 Million
Q2 2018 Aug 13, 2018	BUY	$26.0 - $29.9 $3.25 Million - $3.74 Million	125,000 New	125,000 $3.74 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.